Bone and tissue changes following prostaglandin therapy in neonates

Annals of Pharmacotherapy

Volumn 30, Issue 3, 1996, Pages 269-277

  Kaufman, Michele B ^a,b   El Chaar, Gladys M ^a,c  

^a ST JOHN'S UNIVERSITY   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c SCHNEIDER CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCITONIN; CALCIUM; PARATHYROID HORMONE; PHOSPHATE; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA;

ARTICLE; BONE DISEASE; CELL PROLIFERATION; CONGENITAL HEART MALFORMATION; CORTICAL BONE; CRANIAL SUTURE; DRUG MONITORING; ENZYME BLOOD LEVEL; GESTATIONAL AGE; HUMAN; HYPEROSTOSIS; INTRAVENOUS DRUG ADMINISTRATION; NEWBORN; NONHUMAN; PERIOSTEUM; PHARMACIST; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SOFT TISSUE DISEASE;

ALPROSTADIL; BONE AND BONES; DINOPROSTONE; EDEMA; HUMANS; HYPEROSTOSIS; INFANT, NEWBORN; OXYTOCICS; PLATELET AGGREGATION INHIBITORS;

EID: 0029872398     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000311     Document Type: Article

References (29)

1. Elliot RB, Starling MB, Neutze JM. Medical manipulation of the ductus arteriosus. Lancet 1975;1:140-3.
2. Roberts RJ. Prostaglandins, prostaglandin inhibitors, and vitamin E. In: Roberts RJ, ed Drug therapy in infants. Pharmacologic principles in clinical experience. Philadelphia: WB Saunders, 1984:250-83.
3. Luken JA. Prostaglandin therapy of congenital heart disease In: Yeh TF, ed. Neonatal therapeutics. Baltimore: Mosby Year Book. 1991:139-46.
4. Product information. Prostin VR Pediatric (alprostadil). Kalamazoo, MI: Upjohn, 1992.
5. McEvoy GK, ed. American hospital formulary service 95 drug information. Bethesda. MD: American Society of Health-Systems Pharmacists, 1995:2244-5.
6. 1 administration. J Pediatr 1980;96:318-20.
7. Poznanski AK, Fernbach SK, Berry TE. Bone changes from prostaglandin therapy. Skeletal Radiol 1985;14:20-5.
8. 1 in infants with cyanotic congenital heart disease. J Pediatr 1980;97:834-6.
9. 2 therapy in two newborn infants. J Pediatr 1984;105:72-4.
10. Williams JL. Periosteal hyperostosis resulting from prostaglandin therapy. Eur J Radiol 1986;6:231-2.
11. 1 therapy. Pediatr Cardiol 1986;7:157-60.
12. 1 therapy. Pediatr Radiol 1986,16:57-8.
13. 1 in an infant with cyanotic congenital heart disease (abstract). Clin Nucl Med 1987;12:74.
14. 1 in an infant Clin Pediatr 1987;26:302-3.
15. 1 therapy in infants with ductus-dependent congenital heart disease. Pediatr Radiol 1988;18:149-53.
16. Drvaric DM, Parks J, Wyly JB, Dooley KJ, Plauth WH, Schmitt EW. Prostaglandin-induced hyperostosis: a case report. Clin Orthop 1989;246:300-4.
17. Rowley RF, Lawson JP. Case report 701. Skeletal Radiol 1991;20:617-9.
18. Matzinger MA, Briggs VA, Dunlap HJ, Udjus K, Martin DJ, McDonald P Plain film and CT observations in prostaglandin-induced bone changes. Pediatr Radiol 1992;22:264-6.
19. 1 infusion in an infant with congenital heart disease. Radiology 1982;142:657-8.
20. Neithammer JG, Rule KA, Lorch V, Anderson ME. Periosteal reaction iduced by prostaglandins. Am J Perinatal 1992;9:279-80.
21. Ringel RE, Haney PJ, Brenner JI, Mancuso TJ, Roberts GS, Moulton AL, et al. Periosteal changes secondary to prostaglandin administration. J Pediatr 1983;103:251-3.
22. Woo K, Emery J, Peabody J. Cortical hyperostosis: a complication of prolonged prostaglandin infusion in infants awaiting cardiac transplantation. Pediatrics 1994:93:417-20.
23. 2 on cancellous and cortical bone in young adult dogs. Bone 1990;11:353-64.
24. 2 on maintaining elevated proximal tibial metaphyseal cancellous bone mass in male rats. Calcif Tissue Int 1992;50:245-52.
25. The pathogenesis and investigation of metabolic bone disease. In: Campbell C, Compston J, Crisp A, eds. The management of common metabolic bone disorders. New York: Cambridge University Press, 1993:1-28.
26. Osseous development. In: Marcove RC, Arlen M, eds. Atlas of bone pathology with clinical and radiographic correlations. Philadelphia: Lippincott, 1992:1-33.
27. Swaminathan R. Disorders of metabolism 2. Shetty HGM, Routledge PA, Davies DM. Disorders of muscle, bone, and connective tissue. In: Davies DM, ed. Textbook of adverse drug reactions. New York: Oxford University Press, 1991:416-21,495.
28. Dukes MNG, ed. Meyler's side effects of drugs. New York: Elsevier, 1992:513,938,987-8.
29. Resnick D. Disorders due to medications and other chemical agents. In: Resnick D, ed. Diagnosis of bone and joint disorders. Philadelphia: WB Saunders, 1995:3333-4.